Results 81 to 90 of about 125,678 (274)

Validity of a Wearable Digital Insole for Assessing Gait ON and OFF in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Gait impairment is a distinctive symptom of Parkinson's disease that negatively impact mobility. We assessed the validity of wearable digital insoles against a validated reference gait analysis system for measuring select gait characteristics in patients with Parkinson's disease. Methods A comparative analysis between digital insoles
Deborah A. Hall, Kimberly Kwei, Rolando J. Acosta, Bharatkumar Koyani, Erin Robertson, Pratyush Rai, Roland Barge, Emily Timm, Nicollette L. Purcell, Natasha Desai, Dhanesh Patel, Ana‐Maria Visoiu‐Knapp, Samuel Stuart, Rinol Alaj, Matthew F. Wipperman, Oren Levy, Joan A. O'Keefe   +16 more
wiley   +1 more source

Piece of Mind: knowledge translation performances for public engagement on Parkinson’s disease and dementia

Frontiers in Psychology
IntroductionThe subjective experience of illness is often overshadowed by the disease-and-cure focus of health research, contributing to the stigmatization of conditions such as Parkinson’s disease and dementia.
Naila Kuhlmann, Naila Kuhlmann, Aliki Thomas, Aliki Thomas, Natalia Incio-Serra, Stefanie Blain-Moraes   +5 more
doaj   +1 more source

Imaging Studies of Aging, Neurodegenerative Disease, and Alcoholism. [PDF]

, 1995
Neurodegenerative diseases such as Alzheimers disease, disorders such as alcoholism, and the aging process can lead to impaired cognitive function and dementia.
Eberling, Jamie, JAGUST, William J
core  

The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen [PDF]

, 2011
Increased brain α-synuclein (SNCA) protein expression resulting from gene duplication and triplication can cause a familial form of Parkinson's disease (PD).
Bandyopadhyay, Sanghamitra, Cahill, Catherine M., Castelvetri, Ippolita Cantuti, Greig, Nigel H., Huang, Xudong, Lahiri, Debomoy K., Maccecchini, Maria L., Mikkilineni, Sohan, Rogers, Jack T., Smith, Deborah H.   +9 more
core   +1 more source

Baseline Regional Cholinergic Denervation Predicts Cognitive Trajectories in Moderate Parkinson Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cognitive decline is a disabling and variable feature of Parkinson disease (PD). While cholinergic system degeneration is linked to cognitive impairments in PD, most prior research reported cross‐sectional associations. We aimed to fill this gap by investigating whether baseline regional cerebral vesicular acetylcholine transporter ...
Taylor Brown, Giulia Carli, Prabesh Kanel, Stiven Roytman, Jaimie Barr, Nicolaas I. Bohnen, Roger L. Albin   +6 more
wiley   +1 more source

High delta and gamma EEG power in resting state characterise dementia in Parkinson’s patients

Biomarkers in Neuropsychiatry, 2020
Background: Parkinson’s disease (PD) is a chronic neurodegenerative disease with appearance of dementia as the disease progresses. Dementia in PD worsens the quality of life and poses a burden on caregivers.
Anita Pal, Nishi Pegwal, Madhuri Behari, Ratna Sharma   +3 more
doaj   +1 more source

Effects of dance therapy on balance, gait and neuro-psychological performances in patients with Parkinson's disease and postural instability [PDF]

, 2012
Postural Instability (PI) is a core feature of Parkinson’s Disease (PD) and a major cause of falls and disabilities. Impairment of executive functions has been called as an aggravating factor on motor performances. Dance therapy has been shown effective
Agnetti, Virgilio, Aiello, Elena, De Natale, Edoardo, Deriu, Franca, Paulus, Kai Stephan, Sotgiu, Giovanni, Tolu, Eusebio   +6 more
core  

Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders. [PDF]

, 2019
Purpose of reviewThe aim of this study was to examine the synaptic biomarker neurogranin in cerebrospinal fluid (CSF) in different stages of HIV infection and in relation to what is known about CSF neurogranin in other neurodegenerative diseases.Recent ...
Blennow, Kaj, Fuchs, Dietmar, Gisslén, Magnus, Price, Richard W, Spudich, Serena, Yilmaz, Aylin, Zetterberg, Henrik   +6 more
core   +2 more sources

Clinical Validation of Plasma p‐217tau in Neurological Diseases

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi, Takumi Nakamura, Ryoma Takahashi, Tetsuya Ueda, Seiji Kinoshita, Chikage Uchida, Takashi Sugawara, Kentaro Hashimoto, Kunihiko Ishizawa, Masakuni Amari, Hiroo Kasahara, Yoshio Ikeda, Masamitsu Takatama, Mikio Shoji   +13 more
wiley   +1 more source

Can the CERAD neuropsychological battery be used to assess cognitive impairment in Parkinson's disease?

Arquivos de Neuro-Psiquiatria
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropsychological battery was created to assess cognitive impairment in Alzheimer's disease (AD) but it is widely-used for various dementias. The aim of this study was to analyze the
Carlos Henrique Ferreira Camargo, Augusto Bronzini, Eduardo de Souza Tolentino, Camila Medyk, Gustavo Leopold Schultz-Pereira   +4 more
doaj   +1 more source